Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 9/20 | 0.64 |
| ▸ | NOS3 | P29474 | 2/20 | 0.62 |
| ▸ | NOS2 | P35228 | 2/20 | 0.62 |
| ▸ | CASP7 | P55210 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | PAH | P00439 | 1/20 | 0.50 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.37 |
| ▸ | FPGS | Q05932 | 2/20 | 0.37 |
| ▸ | GART | P22102 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16741181 | 0.98 | NOS1 (0.62) | NOS1NOS3NOS2CASP7HSD17B10 | |
| SCHEMBL2044797 | 0.78 | NOS1 (0.78) | NOS1NOS3NOS2CASP7HSD17B10 | |
| SCHEMBL4649231 | 0.78 | NOS1 (0.72) | NOS1NOS3NOS2CASP7HSD17B10 | |
| SCHEMBL4649233 | 0.78 | NOS1 (0.72) | NOS1NOS3NOS2CASP7HSD17B10 | |
| SCHEMBL9248337 | 0.78 | NOS1 (0.72) | NOS1NOS3NOS2CASP7HSD17B10 | |
| SCHEMBL25737619 | 0.78 | NOS1 (0.53) | NOS1NOS3NOS2CASP7HSD17B10 | |
| SCHEMBL19410958 | 0.77 | NOS1 (0.59) | NOS1NOS3NOS2CASP7HSD17B10 | |
| SCHEMBL10615701 | 0.77 | NOS1 (0.71) | NOS1NOS3NOS2CASP7HSD17B10 | |
| SCHEMBL188413 | 0.77 | NOS1 (0.56) | NOS1NOS3NOS2CASP7HSD17B10 | |
| SCHEMBL156195 | 0.76 | KDM4E (0.57) | NOS1NOS3NOS2CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119925601-A | Application of tetrahydrobiopterin pathway as target in anti-QDPR deletion type tumor | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-05-06 | — | — | CN | claimed |
| WO-2024084421-A1 | TREATMENT OF VASCULAR DISEASES ASSOCIATED WITH GENETIC VARIATIONS IN ACTA2 | QRGENETICS LTD. (IL) | 2024-04-25 | — | — | WO | claimed |
| CN-114558141-A | Promoter for reducing malignant phenotype of pancreatic cancer cells, pharmaceutical composition and application thereof | 新乡医学院 | 2022-05-31 | — | — | CN | claimed |
| CN-113342109-B | Low dropout regulator with maximum current limiting function | 电子科技大学 | 2022-04-22 | — | — | CN | claimed |
| WO-2019175328-A1 | BH4PATHWAYACTIVATIONANDUSETHEREOFFORTREATINGCANCER | IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH (AT) | 2019-09-19 | — | — | WO | claimed |
| US-20080221111-A1 | Roflumilast and sepiapterin; (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; prevention, treatment of respiratory diseases | NYCOMED GMBH (DE) | 2008-09-11 | — | — | US | claimed |
| EP-1940392-A2 | COMBINATION OF THE PDE4 INHIBITOR AND A TETRAHYDROBIOPTERIN DERIVATIVE | Nycomed GmbH (DE) | 2008-07-09 | — | — | EP | claimed |
| WO-2006120176-A2 | COMBINATION OF THE PDE4 INHIBITOR ROFLUMILAST AND A TETRAHYDROBIOPTERIN DERIVATIVE | NYCOMED GMBH (DE) | 2006-11-16 | — | — | WO | claimed |
| WO-2005018620-A2 | USE OF NITRIC OXIDE SYNTHASE (NOS) COFACTOR FOR THE TREATMENT OF SEXUAL DYSFUNCTION | CELL CENTER COLOGNE GMBH (DE) | 2005-03-03 | — | — | WO | claimed |
| JP-5194229-A | — | — | None | — | — | JP | disclosed |
| JP-63267781-A | — | — | None | — | — | JP | disclosed |
| US-20250312488-A1 | TARGETED INTEGRATION AT ALPHA-GLOBIN LOCUS IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250255873-A1 | RESTORING FUNCTION OF SPECIFIC MUTATIONS AFFECTING THE ACTIN DYNAMIC BY ADMINISTRATION OF SAPROPTERIN | QRGENETICS LTD. (IL) | 2025-08-14 | — | — | US | disclosed |
| CN-119925601-A | Application of tetrahydrobiopterin pathway as target in anti-QDPR deletion type tumor | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-05-06 | — | — | CN | disclosed |
| US-4758571-A | Pterin derivatives to treat Parkinson's disease | KANEGAFUCHI CHEMICAL INDUSTRY COMPANY, LIMITED (JP) | 1988-07-19 | — | — | US | disclosed |
| EP-0138995-A4 | REGULATION OF ENZYMES WHICH UTILIZE TETRAHYDROBIOPTERIN OR TETRAHYDROFOLATE COFACTORS WITH 6, 6-DISUBSTITUTED-TETRAHYDROPTERIDINES. | UNIV SOUTH ALABAMA (US) | 1988-05-10 | — | — | EP | disclosed |
| EP-0209689-A2 | Use of tetrahydrobiopterins in the preparation of a medicament for the treatment of infantile autism | SUNTORY LIMITED (JP) | 1987-01-28 | — | — | EP | disclosed |
| EP-0138995-A1 | REGULATION OF ENZYMES WHICH UTILIZE TETRAHYDROBIOPTERIN OR TETRAHYDROFOLATE COFACTORS WITH 6, 6-DISUBSTITUTED-TETRAHYDROPTERIDINES. | UNIV SOUTH ALABAMA (US) | 1985-05-02 | — | — | EP | disclosed |
| US-4500524-A | Tranquilizing and reducing or preventing seizures | TRUSTEES OF BOSTON UNIVERSITY (US) | 1985-02-19 | — | — | US | disclosed |
| WO-1984004040-A1 | REGULATION OF ENZYMES WHICH UTILIZE TETRAHYDROBIOPTERIN OR TETRAHYDROFOLATE COFACTORS WITH 6, 6-DISUBSTITUTED-TETRAHYDROPTERIDINES | UNIV SOUTH ALABAMA (US) | 1984-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255873-A1 | RESTORING FUNCTION OF SPECIFIC MUTATIONS AFFECTING THE ACTIN DYNAMIC BY ADMINISTRATION OF SAPROPTERIN | ACTR2, ACTB, ACTR3 | NOS1 2695/4885NOS3 3271/4885NOS2 1672/4885 |
| US-20080221111-A1 | Roflumilast and sepiapterin; (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; prevention, treatment of respiratory diseases | SPR, PAH, QDPR | NOS1 264/4885NOS3 173/4885NOS2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.